SkyePharma "optimistic" ahead of crucial year
This article was originally published in Scrip
Executive Summary
SkyePharma reported a positive set of results for 2010, ahead of a crucial year for the UK drug delivery specialist. It is "optimistic" of both approval and launch of its combination asthma product Flutiform (fluticasone propionate plus formoterol fumarate) in Europe this year, new CEO Dr Axel Müller told Scrip.